Archives | LinksMedicus Free Medical News & Perspectives

In an RCT, 1905 patients with left main coronary artery disease were assigned to either PCI or CABG. At five years, rates of the composite of death, stroke, or MI were not significantly different between the two groups. See the EXCEL trial. #TCT2019 https://t.co/wlpE5FPTwT

— NEJM (@NEJM) September 28, 2019

Review: Understanding Acute Burn Injury as a Chronic Disease

30 Sep, 2019 | 00:47h | UTC

Understanding acute burn injury as a chronic disease – Burns & Trauma (free)

Global Burden of Cancer, 1990 to 2017

30 Sep, 2019 | 00:42h | UTC

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study – JAMA Oncology (free)

Related Commentary on Twitter

To ensure sustainable global development, increased efforts are needed in cancer prevention and in ensuring universal access to cancer care. https://t.co/6HDaU8Ped9

— JAMA Oncology (@JAMAOnc) September 27, 2019

#ESMO19 – Randomized Trial: Improved Overall Survival with a CDK4/6 Inhibitor for Hormone Receptor-positive, ERBB2-negative Advanced Breast Cancer

30 Sep, 2019 | 00:40h | UTC

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial – JAMA Oncology (free)

Commentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

[Abstract Only] Randomized Trial: Standard Valsalva vs. Modified Valsalva for Cardioversion of SVT

30 Sep, 2019 | 00:14h | UTC

Standard Valsalva vs Modified Valsalva for Cardioversion of SVT? – REBELEM (free)

Original Study: A multicenter randomized controlled trial of a modified Valsalva maneuver for cardioversion of supraventricular tachycardias – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

#ESMO19 – [Not Published Yet] Randomized Trial: Many Men with Prostate Cancer May Avoid Postoperative Radiotherapy, Study Suggests

30 Sep, 2019 | 00:39h | UTC

Men with Prostate Cancer can be Spared Radiotherapy after Surgery [ESMO 2019 Press Release] (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

30 Sep, 2019 | 00:37h | UTC

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

Related Commentary on Twitter

With a 5-year min follow-up, the combination of nivolumab plus ipilimumab associated with 5-year survival of 52% in patients with metastatic #melanoma, compared with 44% for nivolumab alone and 26% for ipilimumab alone. See the CheckMate 067 trial. #ESMO19 https://t.co/f50KNzH5tp

— NEJM (@NEJM) September 28, 2019

#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer

30 Sep, 2019 | 00:35h | UTC

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC – European Society for Medical Oncology (free) AND Nivolumab/Low-dose Ipilimumab: A Potential Chemotherapy-Sparing Option in Advanced NSCLC – Pharmacy Times (free)

#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona

Related Commentary on Twitter

Chemo-naïve patients with adv #NSCLC with PD-L1 expression assigned to nivolumab + ipilimumab, nivolumab alone, or chemo. Patients receiving nivolumab + ipilimumab had better clin outcomes. See the CheckMate 227 trial. #ESMO19 https://t.co/jU9S62qZLa

— NEJM (@NEJM) September 28, 2019

Cohort Study: Improved Survival After Mohs Micrographic Surgery for Early-Stage Invasive Melanoma

30 Sep, 2019 | 00:12h | UTC

Comparison of Survival After Mohs Micrographic Surgery vs Wide Margin Excision for Early-Stage Invasive Melanoma – JAMA Dermatology (free for a limited period)

Editorial: Improving Survival for Patients With Early-Stage Melanoma (free for a limited period)

Commentaries: Mohs micrographic surgery may up survival in stage I melanoma – MedicalXpress (free) AND Mohs Tied to Better OS in Early Invasive Melanoma – MedPage Today (free registration required)

Review: Treatment of Vulvovaginal Atrophy

30 Sep, 2019 | 00:12h | UTC

Treatment of Vulvovaginal Atrophy – JAMA (free for a limited period)

Randomized Trial: Protocolized Non-invasive vs. Invasive Weaning from Mechanical Ventilation for Adults in Intensive Care

30 Sep, 2019 | 00:16h | UTC

Protocolised non-invasive compared with invasive weaning from mechanical ventilation for adults in intensive care – Health Technology Assessment (free)

Source: Critical Care Reviews Newsletter

“A protocolized non-invasive weaning strategy did not reduce time to liberation from ventilation. However, patients who underwent non-invasive weaning had fewer days requiring IMV and required fewer antibiotics for respiratory infections.”

[Abstracts Only] Biologics Found to be Effective for Ulcerative Colitis in Industry-funded Trials

30 Sep, 2019 | 00:11h | UTC

Biologics found to be effective for ulcerative colitis in industry-funded trials – ACP Gastroenterology (free)

Original Studies: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text) AND Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)

Randomized Trial: Length of Steroid Course for Childhood Nephrotic Syndrome Makes Little Difference to Later Recurrences

30 Sep, 2019 | 00:10h | UTC

Length of steroid course for childhood nephrotic syndrome makes little difference to later recurrences – NIHR Signal (free)

Original Study: Randomized Trial: Long Term Tapering vs. Standard Prednisolone Treatment for First Episode of Childhood Nephrotic Syndrome – The BMJ (free)

WHO 2019 Monitoring Report: Primary Health Care on the Road to Universal Health Coverage

30 Sep, 2019 | 00:09h | UTC

2019 Monitoring Report: Primary Health Care on the Road to Universal Health Coverage – World Health Organization (free)

News Release: Countries must invest at least 1% more of GDP on primary health care to eliminate glaring coverage gaps – World Health Organization (free)

Massive Open Online Courses (MOOCs) for Continuing Medical Education – Why and How?

30 Sep, 2019 | 00:08h | UTC

Massive open online courses (MOOCs) for continuing medical education – why and how? – Advances in Medical Education and Practice (free)

Randomized Trial: New Antibiotic Seems Effective for Community-Acquired Bacterial Pneumonia

30 Sep, 2019 | 00:07h | UTC

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Lefamulin—A New Antibiotic for Community-Acquired Pneumonia (free for a limited period)

Related Commentary on Twitter

Among patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to early clinical response at 96 hours after first dose https://t.co/wwQrx79kFq

— JAMA (@JAMA_current) September 28, 2019

Fri September 27 – 10 Stories of The Day!

27 Sep, 2019 | 08:36h | UTC

1 – Diagnosis and management of Guillain–Barré syndrome in ten steps – Nature Reviews Neurology (free)

2 – Should antidepressants be used for major depressive disorder? – BMJ Evidence-Based Medicine (free)

Related Commentary: Do Antidepressants Work? – The New York Times (10 articles per month are free)

“Generally, all the previous reviews show that antidepressants seem to have statistically significant effects on depressive symptoms, but the size of the effect has questionable importance to most patients.”

3 – Clinical Approach to Lactose Intolerance – JAMA (free for a limited period)

4 – Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery – Cochrane Library (free)

Summary: Beta-blockers to prevent death or serious events after surgery not involving the heart – Cochrane Library (free)

5 – Over-the-Counter Access to Hormonal Contraception – American College of Obstetricians and Gynecologists (free)

Summary: Over-the-Counter Access to Hormonal Contraception (free)

News Release: ACOG Updates Guidance on Over-the-Counter Access to Hormonal Contraception (free)

Commentaries: Hormonal Contraceptives Should Be Available OTC, ACOG Recommends – NEJM Journal Watch (free) AND All hormonal birth control should be available over the counter, OB-GYN group says – NBC News (free)

6 – Total Hip Arthroplasty or Hemiarthroplasty for Hip Fracture – New England Journal of Medicine (free)

Commentary: International study finds similar results from total or partial hip replacement – McMaster University (free)

7 – Ticagrelor with or without Aspirin in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention – TWILIGHT – American College of Cardiology (free) AND TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events – TCTMD (free)

8 – Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial – JAMA Network Open (free)

Commentaries: BCG Vaccination and Cancer Risk: What’s the Link? – MPR (free) AND BCG Vax: A Shot Against Lung Cancer in Native Populations? – MedPage Today (free)

9 – This is how attitudes to vaccines compare around the world – World Economic Forum (free)